Abstract Stem cell transplantation from HLA-haploidentical related donors (haploSCT) has been highlighted as an alternative donor source. The regimen consisting of post-transplant cyclophosphamide (PTCY) has been highly prevalent in the US, Europe, and Japan. Considering the status overseas and the current status in Japan, we aim to show our efforts in haploSCT. We initially established the "haplo-full (original)" regimen, which was found to be excessively toxic for general use. Thus, we added ATG to diminish the GVH reaction (haplo-full with ATG). Unfortunately, "haplo-mini (original)" was found to be relatively weak against refractory diseases. Thus, we intensified the preconditioning regimen, which has enabled us to deal with refractory and post-transplant relapse (FAMC-T). One of the characteristics in haploSCT in Hyogo is the use of steroids from the beginning of SCT. The aim of this strategy is to diminish the inflammation affecting GVHD-target organs, and to suppress chemokine release. Since chemokines produced by the preconditioning regimen are well known to induce GVHD, chemokine suppression should effectively suppress GVHD development. The dependency of the GVL effect on chemokines is unclear, possibly serving as a therapeutic window to separate GVHD from the GVL effect.

periventricular hyperintensity (以下PVH) の成り立ちを知るために, 初発脳血栓例のMRT2強調画像でみられたPVHを責任病巣, 血管撮影所見, 危険因子より検討した.対象は脳血栓初回発作例103例 (脳血栓群) で, 対照には高血圧/糖尿病を有する危険因子群37例と, これらのない非危険因子群78例を用いた.責任病巣は大脳皮質 (COR) 型, 半卵円中心 (CSO) 型, 内包-放線冠 (IGCR) 型および脳幹・小脳 (BS) 型の4型に分類すると各々25例, 10例, 46例, 22例あった.PVHは有無, 分布よりnone, rims/caps, patchy, diffuseに分類したが, 広範なPVH (後二者) は脳血栓群や高血圧例で有意に多くみられた.またPVHのうちdiffuseはCSO型や脳主幹動脈狭窄と, patchyはIGCR型と密接な関連を示した成績から, diffuseの成り立ちには主幹動脈病変に基づく血行力学的な機序が, patchyは小動脈病変による虚血の多発, 癒合性変化が考えられた.